REG - Roquefort Theraptcs. - Director/PDMR Shareholding

Roquefort TherapeuticsAnnouncement

30/06/2022 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220630:nRSd8984Qa&default-theme=true

RNS Number : 8984Q  Roquefort Therapeutics PLC  30 June 2022

 

 

30 June 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Director/PDMR Shareholding

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on early-stage opportunities in the biotechnology sector, advises that
Stephen West, Executive Chairman has purchased ordinary shares in the Company
in the market, as detailed below:

 

               Number of Ordinary Shares  Average Price Paid Per Share  Total Consideration Paid

 Name
 Stephen West  289,123                    8.58 pence                    £24,815.91

 

Following the above purchase of shares, Mr West holds interests in the
following Company securities:

 

               Number of Ordinary Shares Held  % of Issued Share Capital  Number of Warrants Held

 Name
 Stephen West  4,839,123                       6.73%                      7,500,000

 

4,399,000 of Mr West's shares are held in the name of Cresthaven Investments
Pty Ltd ATF the Bellini Trust.

 
Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma. The Company is a pre-clinical biotech company focused
on developing first in class Midkine targeting drugs for the treatment of
cancer.

 

Through extensive research resulting in validation through publication in over
1,000 scientific journals, Roquefort Therapeutics has identified the potential
to exploit the broad therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an exclusive licence
to the largest global IP portfolio on Midkine. The Midkine blocking drug
development markets have significant global market potential (in the
multi-billion dollars). Roquefort Therapeutic's pre-clinical program is
currently underway with an initial focus on cancer.

 

This announcement contains inside information for the purposes of Article 7 of
the UK version of Market Regulation (EU) No 596/2014 on Market Abuse as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018, as amended ("UK MAR").

The notification below, made in accordance with the requirements of the UK
MAR, provides further detail:

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities / person closely
     associated
 a)  Name                                                         Stephen West
 2   Reason for the notification
 a)  Position/status                                              Executive Chairman
 b)  Initial notification /Amendment                              Initial
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Roquefort Therapeutics plc
 b)  LEI                                                          254900P4SISIWOR9RH34
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of £0.01 par value

     Identification code

                                                                  ISIN: GB00BMDQ2T15
 b)  Nature of the transaction                                    Purchase of 289,123 ordinary shares
 c)  Price(s) and volume(s)                                       Price(s)                     Volume(s)
                                                                  8.44 pence per share         58,806

                                                                  8.50 pence per share           175,170

                                                                  9.00 pence per share         55,147
 d   Aggregated information

     - Aggregated volume                                          -       289,123

     - Price                                                      -       8.58p
 e)  Date of the transactions                                     30 June 2022
 f)  Place of the transactions                                    London Stock Exchange (XLON); Main Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHBUGDLIXXDGDG